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Randomised trials are distinguished from other clinical 
trials by the way in which the participants are allocated 
to groups. The effect of allocating participants randomly 
is that the groups tend to have similar characteristics, 
especially when many participants are randomised (Altman 
and Bland 1999). Groups with similar characteristics can 
be expected to have similar outcomes. Therefore, if an 
intervention is applied to only one of these groups, the 
difference in outcomes between the groups can be assumed 
to be due to the intervention (Herbert 2005). However, even 
when a random allocation sequence is used, the allocation 
process can be corrupted so that it does not produce groups 
with similar characteristics (Schulz and Grimes 2002). 
The ﬁrst section of this research note will describe how 
a random allocation list can produce dissimilar groups 
when that list is not concealed from the investigators who 
enrol participants in a trial. The second section will review 
practical ways in which the allocation list can be concealed 
from these investigators to ensure that randomisation occurs 
as intended.
Corruption of randomisation by 
knowledge of the allocation list
Consider a randomised trial that enrols hospital inpatients 
with a particular condition and allocates them to two 
groups – intervention and control. If all patients approached 
about participation in the trial were eligible and willing to 
participate and were enrolled consecutively, then patients 
would be allocated according to the random allocation list. 
Randomisation would then work as intended, tending to 
produce groups with similar characteristics. However, in 
most trials, participants are not approached consecutively 
and some patients are ineligible or unwilling to participate. 
At least one investigator must decide which patients to 
approach about the trial and determine which patients are 
eligible to participate. Patients must also be fully informed 
about the details of the trial before deciding whether to 
consent to participate. These three steps – approaching 
patients, determining eligibility, and informing for consent 
– are each an opportunity for some patients not to enrol in 
the trial. If the upcoming allocation on the randomisation 
list is known to the investigator(s) responsible for enrolling 
participants, it may change the way any of these steps is 
conducted and may corrupt the randomisation process.
Approaching patients
An investigator responsible for approaching patients to 
discuss the study may have some freedom about which 
patients to approach and in what order to approach them. 
If the investigator has access to the random allocation list 
and is aware of the upcoming allocation, this may inﬂuence 
his/her behaviour in approaching patients. For example, 
an investigator who hopes that the trial shows that the 
intervention is effective may approach patients with a more 
favourable prognosis when he or she knows that the next 
trial participant is to be allocated to the treatment group. 
Alternatively, the investigator may approach patients with 
the most potential to beneﬁt or the most urgent need for 
beneﬁt when the upcoming allocation is to the treatment 
group. Perhaps the investigator wants to ensure good 
compliance with the intervention and therefore approaches 
well motivated and co-operative patients when the 
upcoming allocation is to the treatment group. Regardless 
of the investigator’s motivation, such changes in the order 
of approaching patients can set up systematic differences 
in the characteristics of the intervention and control 
groups. This, in turn, could bias the estimate of the effect 
of treatment produced by the trial. Although investigators 
may not intend to modify their behaviour in these ways, 
such effects could even happen subconsciously. However, 
if the upcoming allocation is concealed from the enrolling 
investigator, these effects cannot occur.
Determining eligibility
After a patient has been approached and has expressed 
some interest in participating in the trial, an investigator 
must determine whether the patient meets the eligibility 
criteria. Some eligibility criteria (eg, age, gender, the 
presence of a prosthetic joint) may be clear cut with little 
opportunity for interpretation. However, other eligibility 
criteria may be more subjective. For example, in a trial of 
home-based exercise training for people with chronic heart 
failure by Chien et al (2011), one exclusion criterion was a 
primary musculoskeletal disease [affecting] the assessment 
of exercise capacity. All musculoskeletal diseases 
will fall somewhere on a spectrum from substantially 
impairing the assessment of exercise capacity to having 
no effect. In assessing each potential participant against 
this criterion, the enrolling investigator may be forced 
to decide subjectively whether borderline impairment is 
negligible or not. Knowledge of the upcoming allocation 
could affect (consciously or subconsciously) the decision 
about the patient’s eligibility. Similar motivations to those 
discussed above could again systematically inﬂuence which 
patients are allocated to each group. For example, patients 
with a poor prognosis may be deemed ineligible when the 
upcoming allocation is to the treatment group but deemed 
eligible otherwise. Concealment of the allocation list 
prevents this potential source of bias between the groups.
Informing for consent
Patients who are deemed eligible for a trial must make a fully 
informed decision about their willingness to participate 
(World Medical Association 2008). While a comprehensive 
description of all the salient points must be given to each 
interested patient, a standard text is not usually used to 
guide the description. Because the description can vary 
between patients, there is again opportunity for knowledge 
of the upcoming randomisation to affect how the enrolling 
investigator describes trial participation to the patient. For 
example, the negative aspects of trial participation may be 
emphasised if the investigator wants to divert the patient 
away from the upcoming allocation. Such negative aspects 
may include the number of visits required for outcome 
assessment, the possibility of randomisation to the control 
group, and the time, effort and expense of undertaking the 
intervention. Conversely, positive aspects – such as the 
opportunity to receive the results of health-related tests that 
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would be undertaken as part of outcome assessment – could 
be emphasised. Again, this change in the investigator’s 
behaviour may be subconscious.
For simplicity, we have considered the example of a trial 
in which inpatients are allocated to either an intervention 
or control group. However, the same opportunity for 
corruption of the randomisation process can occur when 
two active treatments are compared, when there are three 
or more groups, or when participants are recruited from the 
wider community (Schulz 1995).
Some empirical evidence indicates that the presence or 
absence of concealment in randomised trials is associated 
with the magnitude of bias in estimates of treatment 
effects (Schulz and Grimes 2002). Therefore, it is worth 
considering ways in which a random allocation schedule 
can be concealed.
Methods of concealing the allocation list
A variety of methods can be used to generate the random 
allocations for a trial and this may inﬂuence the measures 
required to conceal upcoming allocations. Among the 
simplest randomisation methods is ﬂipping a coin. If 
investigators faithfully ﬂip the coin for each participant 
only after eligibility and willingness to participate have 
been conﬁrmed, this would effectively conceal each 
upcoming allocation. Although investigators theoretically 
understand the need for group similarity, they may overlook 
its importance and fail to act impartially once they are 
involved in a trial (Schulz 1995). Therefore, given the 
temptation to re-ﬂip a coin, methods of concealment that 
are less easily circumvented may be more convincing to 
those who read the trial’s methods.
Whether a random allocation list is generated by ﬂipping 
a coin, from random number tables, or by a computer, a 
list of allocations for the whole trial can be generated 
prospectively. Each allocation can then be sealed in a 
consecutively numbered envelope by an independent 
investigator and the set of envelopes given to the enrolling 
investigator. When the enrolling investigator wants to enrol 
and randomise a new participant, the participant’s name is 
written on the front of the next available envelope before 
opening the sealed envelope and retrieving the allocation 
from inside. Various modiﬁcations have been developed 
to prevent circumvention of this method of concealment. 
Opaque envelopes are usually used so that the contents 
aren’t visible under a bright light. For an example, see the 
trial of neural tissue stretching for neck and arm pain by 
Nee and colleagues (2012). Carbon paper may be placed 
inside the envelope to ensure that the participant’s name is 
applied to the allocation inside, so that allocations aren’t 
swapped between envelopes. For an example, see the trial 
of calf stretching for plantar heel pain by Radford and 
colleagues (2007).
While envelope-based systems will usually satisfy 
readers of a trial report that randomisation was properly 
implemented, more elaborate procedures may be better 
still. It is preferable that the allocation list is held only 
by an independent agent. This can be achieved by asking 
a colleague – ideally one who is off-site and otherwise 
uninvolved in the study – to generate and retain the random 
allocation list. Investigators must then contact this person 
to enrol a new participant in the study and be informed of 
the next allocation. For an example, see the trial of exercise 
with incorporated breathing techniques for people with 
cystic ﬁbrosis by Reix and colleagues (2012).
Independant assistance with randomisation can be 
purchased from commercial randomisation services. Such 
services can offer 24-hour-a-day randomisation, which 
may be beneﬁcial if participants need to be randomised at 
unpredictable hours, such as within two hours of an injury 
or upon admission to intensive care.
Note that the method of generating the random allocation 
list is distinct from the method of concealment of 
allocation. It is also important to recognise that the method 
of allocation concealment is distinct from blinding. A trial 
may blind participants, therapists, and assessors, but still 
fail to conceal the allocation list (eg, Saunders 1995). Even 
if a trial cannot be blinded, the allocation list should still be 
concealed for the reasons discussed above.
Blocked randomisation
Blocked randomisation can allow partial loss of concealment 
of the allocation list. A blocked randomisation list is 
comprised of blocks of allocations that maintain reasonable 
balance of the group sizes throughout recruitment. For 
example, a trial intended to randomise 60 participants 
may use a list made up of 10 blocks of six allocations, with 
three treatment and three control allocations randomly 
ordered within each block. This ensures that group sizes 
will be similar even if the trial stops recruiting early. 
A potential problem with blocking is that it can threaten 
concealment. If the trial is not blinded the enrolling 
investigators may recognise that the allocations occur in 
balanced blocks of six. Once the allocations to one group 
are used up within a block, the remaining allocations in 
that block can be predicted with certainty. This allows the 
enrolling investigator to know the upcoming allocation for 
a potentially large proportion of participants, exposing the 
trial to the same problems described earlier. Fortunately, 
this is easily solved by randomly varying the size of the 
blocks. The exact size of blocks should not be made public 
in trial protocols or registers prior to completion of the trial.
Concealed allocation in trials of 
physiotherapy interventions
Concealed allocation is not mentioned in the published 
reports of many trials of physiotherapy interventions 
(Moseley et al 2011). This is disappointing because 
concealed allocation is easy to implement and quick to 
describe in the published report. In 2011, only 20% of all 
trials on the Physiotherapy Evidence Database (PEDro; 
www.pedro.org.au) reported having concealed allocation 
(Moseley et al 2011). However, it is encouraging that this 
percentage has been increasing since shortly after the issue 
was ﬁrst described in the literature (Chalmers et al 1986).
Summary
An enrolling investigator can inﬂuence whether patients 
participate in a randomised trial when deciding which 
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patients to approach, when determining their eligibility, and 
when informing them about the trial. Concealed allocation 
is therefore necessary to guard against investigators 
consciously or subconsciously introducing systematic 
differences in the groups. Readers of trial reports should 
take some reassurance from the use of concealed allocation, 
especially when the method of concealment appears 
difﬁcult to circumvent.
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